文献速递认知障碍与痴呆神经肌肉病帕金森病与运动障碍

TDP-43相关神经退行性疾病的概念化与整合分期:综述

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.
PubMed 文献 · JAMA Neurol · 2026-01-01

本文综述提出以TDP-43病理生物学而非临床表型来定义神经退行性疾病,涵盖LATE、多数ALS、包涵体肌炎、多系统蛋白病及约半数FTD。主张将ALS、FTD、LATE等保留为表型描述,并指出病理在症状出现前已开始,为生物标志物和靶向治疗开发提供路线图。

要点

  • TDP-43病理见于LATE、多数ALS、包涵体肌炎、多系统蛋白病及约半数FTD。
  • 建议以病理生物学定义疾病,临床术语仅描述表型表现。
  • 病理在症状出现前已开始,支持早期生物标志物和靶向治疗开发。

核心结论

  • 提出以TDP-43病理生物学定义疾病,为开发生物标志物和靶向治疗提供路线图。

研究设计与样本

  • 综述,基于文献汇总TDP-43相关神经退行性疾病的临床、生物标志物和神经病理数据。

主要发现

  • TDP-43病理见于LATE、多数ALS、包涵体肌炎、多系统蛋白病及约半数FTD。
  • 当前疾病分类基于不同临床表型,尽管这些疾病共享TDP-43生物学。
  • 生物标志物和神经病理数据趋同提示病理在症状出现前已开始。

关键数值与推荐

  • TDP-43病理见于LATE、多数ALS、包涵体肌炎、多系统蛋白病及约半数FTD。

临床怎么用

  • 临床术语如ALS、FTD、LATE可用于描述表型表现,但疾病定义应基于TDP-43病理生物学。
  • 关注症状前阶段,推动反映潜在病理的生物标志物和靶向治疗开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. OBSERVATIONS: Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. CONCLUSIONS AND RELEVANCE: In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Benatar M, Barmada S, Jicha GA, et al. TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review. JAMA Neurol. 2026. PMID: 42636000. doi:10.1001/jamaneurol.2026.2812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。